Mallinckrodt‘s (NYSE: MNK) Stratatech today received FDA approval for its StrataGraft for treating adult patients with thermal burns.
The Bedminister, N.J.-based company designed StrataGraft to treat thermal burns that have intact dermal elements, or remaining deep skin layers, for which surgical intervention is clinically indicated.
“Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient return to the highest level of functionality and independence possible while improving the overall quality of life,” Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, said in a news release. “This approval provides health care professionals a novel way to treat burn wounds.”
The gold standard treatment for many deep burns involves removing damaged, burned skin and replacing it with a skin graft. Skin grafts are often taken from the patien…